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Abstract Photolabeling of partially purified bovine brain 
adenylyl cyclase (AC I) with [~ap]8-N3-ATP led to incorpora- 
• 32  • tlon of P into the 115 kDa catalyst. Further treatment with N- 
chlorosuccinimide, which cleaves proteins at tryptophan residues, 
yielded a 14 kDa 32p-labeled fragment. The latter was 
immunoprecipitated by antibody BBC1, recognizing the extreme 
C-terminus of AC I, but not by antibody BBC2, recognizing a 
more remote epitope. Further fragmentation of photolabeled AC 
I by the proteases GIu-C and Asp-N yielded 32p-labeled peptides 
corresponding to 2.9 kDa and 5.6 kDa fragments, which were not 
recognized by any of these antibodies. This narrows the ATP 
binding site down to a 25 amino acid sequence containing a 
general motif G(X0.7)KG(Xo_4)L/M(Xs.7)S/T present in all 
eukaryotic adenylyl eyclases o far cloned, but also in a variety 
of bacterial adenylyl cyclases (Peterkofsky et al. (1993) Progr. 
Nucleic Acids Res. Mol. Biol. 44, 31-65). 
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1. Introduction 
To date at least eight eukaryotic adenylyl cyclases from 
mammals, insects and slime molds have been cloned and se- 
quenced. For type V adenylyl cyclase several subforms exist 
[1,2]. The presumptive catalytic domains of these adenylyl 
cyclases but also of various guanylyl cyclases exhibit a high 
degree of homology. For adenylyl cyclases the greatest homol- 
ogy resides in the C la  and C2a segments of the cytosolic 
loops [3]. However, the catalytic ATP binding site has not 
been identified so far, because consensus sequences character- 
istic for classical nucleotide binding sites GXXXXGKS as 
present in ATPases or GTPases are missing [4,5]. 
Therefore we started out to localize the ATP binding site(s) 
on type I adenylyl cyclase by reaction with the affinity label 
[y~P]8-N3-ATP and consecutive chemical or enzymatic frag- 
mentation of labeled adenylyl cyclase. This ATP analog has 
been previously used by Castets et al. [6] for labeling of a 
partially purified adenylyl cyclase from rat brain synapto- 
somes. Since photoaffinity labeling usually proceeds with 
low efficiency and 32p-labeled peptides, due to addition of 
several negative charges, may migrate differently from unla- 
beled peptides, precipitation by specific antibodies against 
adenylyl cyclase was used to check coincidence of labeling 
and immunoreactivity. Among the antibodies used, antibody 
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BBC1 was shown to be specific for the calmodulin-dependent 
adenylyl cyclase (Mr 115 kDa) from bovine brain while anti- 
body BBC2 (and BBC4) was recognizing a broad variety of 
adenylyl cyclases from different issues and species [7]. 
2. Materials and methods 
2.1. Materials 
N-Chlorosuccinimide, N-acetylmethionine, 2'-deoxy-3'-AMP, 8-N3- 
ATP were from Sigma; creatine phosphate, creatine kinase, alkaline 
phosphatase (molecular biology grade) and endoproteinases Asp-N 
and Glu-C (sequencing grade) were from Boehringer Mannheim; Pan- 
sorbin cells were from Calbiochem and CSPD was purchased from 
Serva. Immobilon transfer membranes were obtained from Millipore. 
[12~I]NaI (carrier free) and [Ta2P]8-N3-ATP (5-15 Ci/mmol) were from 
ICN, [Ta2P]ATP (760 Ci/mmol) and [3H]cAMP (15-30 Ci/mmol) were 
purchased from Amersham. Peptides derived from the sequence of 
AC I (pl12°-A1134 and G985-T 1005) were kindly synthesized by Drs. J. 
Wallach and R. Frank, ZMBH, Heidelberg. 
2.2. Methods 
2.2.1. Miscellaneous. Polyacrylamide gel electrophoresis and im- 
munoblotting were conducted as described previously [7]. Antibodies 
were either radioiodinated [7,8] or labeled with alkaline phosphatase 
for detection by chemiluminescence with CSPD as substrate. Phos- 
phatase was coupled to antibody according to the specifications of the 
distributor. Radioiodinated (Fig. 1) or rainbow protein markers 
(Amersham) were used as Mr standards. Bovine brain cortex adenylyl 
cyclase was prepared according to Pfeuffer et al. [9,10]. The prepara- 
tion after the first forskolin affinity chromatography was used. It had 
a specific activity of 1.58 grnol mg -~ rnin -~. Adenylyl cyclase assays 
were performed in the presence of 5 mM MgC12, 5 mM MnC12 and 
100 lxM forskolin as described earlier [10]. Radioiodination was per- 
formed according to Greenwood and Hunter [11]. 
2.2.2. Cleavage with N-chlorosuccinimide (NCS). This was per- 
formed essentially according to Lischwe and Ochs [12]. Purified bo- 
vine brain adenylyl cyclase [9] in buffer A (10 mM MOPS, 1 mM 
MgCI2, 1 mM EDTA, 1 mM Tween 60 pH 7.4) was treated with 
2.5 volumes of cleavage solution (1 g urea and 2 ml of 50% acetic 
acid) including the indicated concentrations of NCS for 30 min at 
22°C. The reaction was stopped by addition of a 5-fold molar excess 
of N-acetylmethionine and left for a further 30 rain at 22°C. The 
reaction mixture was lyophilized, dissolved in one volume H~O and 
neutralized with Tris base. Protein samples were used either directly 
for SDS gel electrophoresis after application of sample buffer (Fig. 1) 
or for immunoprecipitation with the monoclonal ntibody BBC1 after 
diluting the solution to 1 M urea and adjusting to RIPA buffer con- 
ditions (0.5% SDS, 1% NP40 and 1% deoxycholate, 150 mM NaC1, 10 
mM sodium phosphate, pH 7.4) (Fig. 3). 
2.2.3. Photolabeling of adenylyl cyclase. Unless specified other- 
wise, adenylyl cyclase in buffer A was concentrated 5-10-fold by cen- 
trifugation through a Microcon 30 filter device (Amicon). Solutions 
were adjusted to 5 mM MnC12 following the protocol of Castets et al. 
[6]. Photolabeling was performed on ice in microtiter plates (30-60 ~tl 
per well). Reaction was started by addition of 50 IxM [y~2p]8-N3-ATP 
(5-15 Ci/mmol) and irradiation at 254 nm with a low intensity UV 
lamp (Camag) for 10 min directly on top of the wells. Photolysis was 
followed either by TCA precipitation or by immunoprecipitation in 
the dark. For precipitation by TCA, the reaction was stopped by 
addition of 10 mM DTT, 1 mg/ml soybean trypsin inhibitor (as car- 
rier protein) and 9 volumes of ice-cold 10% TCA and left on ice for 5 
0014-5793/96l$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
PII S00 1 4- 579 3(96)007 3 5- 1 
210 
min. Protein was collected by centrifugation and the pellet washed 
with ice-cold acetone. The dried protein was dissolved in sample buf- 
fer and applied to 5-15% polyacrylamide SDS gel electrophoresis 
according to Laemmli [13]. 
2.2.4. lmmunoprecipitation with monoclonal antibody BBC1. For 
immunoprecipitation, monoclonal antibody BBC1 was coupled to 
Pansorbin as described earlier [8]. Prior to precipitation, solutions 
were adjusted to RIPA buffer conditions and mixed with the BBC1/ 
Pansorbin complex (200 ~tl of a 20% slurry per ml adenylyl cyclase). 
The slurry was agitated for 2 h at room temperature. Following cen- 
trifugation, the pellet was washed twice with RIPA buffer, once with 
buffer A, suspended in buffer A (50% slurry) and finally stored at 
-20°C. For fragmentation experiments, adenylyl cyclase was eluted 
from the BBC1/Pansorbin complex with 0.5% SDS at 50°C for 10 min 
and separated from the pansorbin by centrifugation. 
2.2.5. Fragmentation of labeled adenylyl cyclase by endoprotea- 
ses. BBCl-purified radiolabeled adenylyl cyclase in buffer A was 
diluted with 4 volumes of 50 mM sodium phosphate pH 8.0 (Asp- 
N) or 25 mM (NH4)2CO3 buffer pH 7.8 (Glu-C) to a final SDS 
concentration f 0.1%. For optimal fragmentation the mixtures were 
supplemented with 0.2% Triton X-100. Reactions were started by 
adding 0.2 ~tg Asp-N or 5 ~tg GIu-C per 100 p~l, maintained at 37°C 
(Asp-N) or 25°C (GIu-C) for 6 h and stopped either with Laemmli 
sample buffer or with SDS (final concentration 0.5%) at 60°C for 10 
min. For immunoprecipitation s lutions were adjusted to RIPA buffer 
conditions. 
3. Results and discussion 
Fig. 1 shows the fragmentation pattern of bovine brain 
adenylyl cyclase obtained by controlled NCS cleavage at tryp- 
tophan residues visualized by two different monoclonal anti- 
bodies. Antibody BBC1 detected four fragments with Mrs 14, 
35, 46 and 79 kDa, expected from the amino acid sequence of 
BBCI  BBL"2 
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Fig. 1. Analysis of NCS-treated bovine brain adenylyl cyclase with 
monoclonal antibodies BBC1 and BBC2. 365 ng each of purified 
adenylyl cyclase were cleaved at tryptophan residues, using the indi- 
cated NCS concentration as described in Section 2. Samples were 
separated on a 5-15% SDS polyacrylamide g l, blotted onto nitro- 
cellulose and probed with radioiodinated antibodies BBC1 or BBC2. 
Molecular masses of radioiodinated standards (BioRad) and NCS 
fragments are marked on the left hand and right hand side, respec- 
tively. 
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Fig. 2. Photoatfinity labeling of purified bovine brain adenylyl cy- 
clase with [~2P]8-N3-ATP. A: Purity of adenylyl cyclase prepara- 
tion. 15 ng of purified adenylyl cyclase was radioiodinated as de- 
scribed in Section 2 and electrophoresed on a 5-15% SDS 
polyacrylamide gel according to Laemmli [13]. The gel was dried 
and exposed to a film for 15 h. B: Specificity of radiolabeling. 290 
ng each of purified adenylyl cyclase were labeled with [~2p]8-Na- 
ATP without prior concentration, precipitated with TCA as de- 
scribed in Section 2 and electrophoresed on a 5-15% SDS polyacryl- 
amide gel. The dried gel was autoradiographed for 2 days. The la- 
beled 115 kDa bands were excised from the gel and measured by 
Cerenkov radiation. The percentage of radiolabeling relative to con- 
trol is given in brackets, lane 1 : control [100%]; lane 2: no UV irra- 
diation [0%]; lane 3: addition of 500 ~tM ATP [42%]; lane 4: addi- 
tion of 500 IxM 2'-deoxy,3'-AMP [80%]; lane 5: addition of 500 
I.tM adenosine [85%]. 
type I adenylyl cyclase [3]. No fragments due to the closely 
spaced tryptophans W 166 and W 213 could be observed. From a 
series of synthesized oligopeptides covering the 14 kDa frag- 
ment (Wl), one 15 amino acid peptide representing the ex- 
treme C-terminus, completely blocked immunostaining by 
BBC1 (not shown). Antibody BBC2, in contrast, was recog- 
nizing only the three higher Mr fragments. At the same time 
its total immunoreactivity gradually disappeared when the 
concentration of NCS increased. This suggested that the site 
of recognition must be located around the C-terminal trypto- 
phan (W1°°2). Consequently the synthetic 21 amino acid pep- 
tide Ggss-T 1°°5, incidentally a highly conserved sequence, in- 
cluding this tryptophan was able to compete effectively with 
the cyclase for antibody BBC2 in Western blots and immuno- 
precipitation (not shown). The characteristic fragmentation 
pattern and the fact that BBC2 recognizes a well conserved 
epitope argue that purified brain adenylyl cyclase used in this 
study consists of only one adenylyl cyclase isoform, namely 
AC I. This was remarkable, since the enzyme was purified by 
forskolin-affinity chromatography from bovine brain cortex 
known to contain more than one adenylyl cyclase isoform 
[7]. Since purification was conducted with 'basal' enzyme 
(i.e. not activated with A1F~- or GTP analogs), other isoforms 
apparently have been lost due to limiting affinity for forskolin. 
Contamination by other impurities was further precluded 
since fragmentation was performed after the labeled enzyme 
had been isolated with the type I specific antibody BBC1. 
8-N3-ATP used as affinity label had an affinity comparable 
to that of natural substrate ATP. Lineweaver-Burk analysis 
revealed a Km of 49 tiM for ATP and a Ki of 49 ~tM for 8-Nz- 
ATP, in the presence of 5 mM MnC12 and 100 ~tM forskolin, 
comparable to previously obtained Km values of 30-60 ~tM 
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for AC I [14], AC II and AC VI [15]. Inhibition by 8-N3-ATP 
proved to be of purely competitive type (not shown). 
Fig. 2A shows an autoradiograph of the radioiodinated, 
partially purified type I adenylyl cyclase used in this study, 
after SDS electrophoresis. Aside from the Mr 115 kDa band 
corresponding to AC I several impurities of Mrs 90, 53, 35 
and 29 kDa are obvious. 
Photoinduced incorporation of [y32P]8-Na-ATP into this 
adenylyl cyclase sample is demonstrated in Fig. 2B which 
shows an autoradiograph after SDS gel electrophoresis. Spe- 
cificity of labeling of the 115 kDa protein was evident from 
inclusion of excessive unlabeled ATP (10-fold) reducing incor- 
porated radioactivity by some 60%, while the P-site inhibitors 
adenosine and 2'-deoxy-3'-AMP at the same concentration 
were less (15-20%) efficient. Practically no radiolabeling was 
measurable when the UV irradiation was omitted, demon- 
strating that incorporation was not due to phosphate transfer 
by a kinase contamination. 
In the following the location of the ATP binding site was 
approached by fragmentation of the labeled enzyme by chem- 
ical and enzymatic means. Fig. 3A shows that [y~zP]8-Na-ATP 
incorporated into the Mr 115 kDa protein was completely 
precipitated by the AC I specific antibody BBC1 coupled to 
Pansorbin cells (lane P). Following cleavage of the labeled 
catalyst at tryptophan (W) residues, the 3zp was mainly found 
in a fragment of Mr 14 kDa (Fig. 3B, lane T). As expected 
from the results in Fig. 1, the labeled 14 kDa fragment was 
almost quantitatively precipitated by the antibody BBC1 (lane 
P). These findings together were indicative for the ATP label 
being attached to the C-terminal 14 kDa fragment of AC I. 
To further narrow down the site of ATP binding, fragmen- 
tation of labeled adenylyl cyclase by the proteases Asp-N and 
A)  k lh  B)  Idle NC$ 
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Fig. 3. Immunoprecipitation by antibody BBC1 of [y32P]8-Na-ATP 
labeled adenylyl cyclase before (A) and following (B) NCS treat- 
ment. A: 180 ng of purified brain adenylyl cyclase was labeled and 
immunoprecipitated with antibody BBC1 as described in Section 2. 
Protein samples were supplied with Laemrnli sample buffer and elec- 
trophoresed on a 5-15% SDS-polyacrylamide g l. The dried gel was 
exposed to the film for 3 days. B: 630 ng of purified bovine brain 
adenylyl cyclase was radiolabeled, immunoprecipitated with the 
monoclonal antibody BBC1 and specifically cleaved at tryptophan 
residues with 5 mM NCS as described in Section 2. The lyophilized 
protein pellet was dissolved in RIPA buffer and immunoprecipitated 
with BBC1. Protein samples were supplied with Laemmli sample 
buffer, electrophoresed on a 5-15% SDS-polyacrylamide gel and 
blotted onto Immobilon membrane. The membrane was autoradio- 
graphed for 3 days. T = total sample; P= immunoprecipitate; S =super- 
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Fig. 4. Fragmentation f [~2P]8-N3-ATP labeled AC I by endopro- 
teases Asp-N and Glu-C. A: Analysis of Asp-N fragments by im- 
munoprecipitation with BBC1. 420 ng radiolabeled and immunopre- 
cipitated AC I was treated with Asp-N as described in Section 2. 
Peptides were immunoprecipitated with BBC1 and separated on a 
7-25% SDS-polyacrylamide g l. Autoradiography of the dried gel 
was performed for 5 days. T = total sample; P = immunoprecipitate; 
S = supernatant from immunoprecipitation. B: Analysis of Glu-C 
and Asp-N fragments on a low Mr range SDS gel. ['Ia2P]8-N3-ATP 
labeled adenylyl cyclase, 230 ng each, was treated with Glu-C (lanes 
1 and 2) or Asp-N (lane 3) as described in Section 2. Samples were 
separated by SDS-gel electrophoresis (16.5% acrylamide, 0.5% bisa- 
crylamide [16]) and transferred onto Immobilon membrane. Blotted 
peptides were either autoradiographed for 5 days (lanes i and 3) or 
irnmunostained with antibody BBC2 (lane 2). 
Glu-C was performed (Fig. 4). Treatment of labeled adenylyl 
cyclase with Asp-N yielded two fragments of Mrs 12.7 (D1- 
D2) and 6.5 kDa (D2, theoretical Mr 5.6 kDa) (Fig. 4A). Only 
the larger one was precipitated by the BBC1 antibody (lane 
P), indicating that the label was not attached to the extreme 
C-terminus. Regarding the sequence of AC I, the smaller pep- 
tide should result from cleavage at D 1°13 and D 1°62 (D2) while 
the 12.7 kDa peptide results from cleavage at D 1°13 (D1-D2) 
(see scheme in Fig. 5). 
Further information was obtained from the app!ication of 
the endoprotease Glu-C. The results shown in Fig. 4B are 
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Fig. 5. Carboxy-terminal cleavage sites of AC I. Numbers indicate theoretical cleavage sites by NCS (W), Asp-N (D), Glu-C (E) and the C ter- 
minus (1134). Putative binding sites of monoclonal antibodies BBC1 and BBC2 are also indicated. Radiolabeled fragments are marked by 
shaded boxes. 
representing an autoradiograph of an immobilon blot of an 
SDS gel prepared according to Schfigger and von Jagow [16] 
which is useful for the separation of small peptides. From lane 
1 it is obvious that the smallest radiolabeled peptide obtained 
had an apparent Mr of 4 kDa (E4, theoretical Mr 2.9 kDa). 
As a further criterion however, antibody BBC2 failed to de- 
tect a peptide of this size in Western blots (lane 2) as it failed 
to precipitate protein-bound radioactivity (not shown). It did 
however detect a somewhat larger peptide (E5) running at 
approx. Mr of 7.3 kDa (theoretical Mr 6.4 kDa, lane 2). 
For a proper comparison, lane 3 shows the radiolabeled D2 
fragment from another (more complete) Asp-N cleavage x- 
periment, running in the Sch/igger gel system at an Mr of 5.0 
kDa. 
Knowledge of the topology of adenylyl cyclases is extremely 
scarce and information on contact sites with G-protein a and 
]3T subunits is missing. The sole exception is the calmodulin 
binding site on subform AC I, which has been localized by 
site-directed peptides [17] and site-directed mutagenesis [18]. 
There is also no information on where divalent cations like 
Mg 2+ or Ca 2+ bind. The latter has been shown to inhibit 
several subforms of adenylyl cyclase at submicromolar con- 
centration most likely via direct interaction with the catalytic 
moiety of the enzyme [1,19]. Likewise missing is information 
on binding sites of the common activator forskolin and on 
nucleotide binding sites for substrate ATP or the so-called P- 
site inhibitors. 
The primary structure of adenylyl cyclases does not exhibit 
typical nucleotide binding sequences as present in ATPases 
and GTPases; hence the common motif GXXXXGKS is 
missing [4]. Therefore Peterkofsky et al. suggested an alterna- 
tive sequence G(X0_7)KG(X0_4)L(X0_5)S/T found in 12 ade- 
nylyl cyclases of mammalian, bacterial and yeast origin [5]. In 
this modified motif the basic amino acid, mostly lysine, pre- 
cedes rather than follows the second glycine residue. The 
authors have argued that this may be due to the specific mech- 
anistic difference, namely release of P-Pi as opposed to that of 
Pi. 
The purified type I adenylyl cyclase used in this study had 
similar affinities for ATP and 8-N3-ATP which was in contrast 
to the fndings of Casters et al. [6] who found a comparable 
affinity for 8-Na-ATP (22 gM) but a 5-fold higher affinity for 
the substrate ATP. However, this difference may be due to a 
different isoform of adenylyl cyclase for which the authors 
claimed a > 100-fold higher specific activity than that re- 
ported here. Using bovine brain adenylyl cyclase type I, 
[y~2P]8-Na-ATP labeled a single peptide. Incorporation of la- 
bel was efficiently competed by the substrate ATP, but ade- 
nosine or the more potent P-site inhibitor 2'-deoxy-Y-AMP 
were also competitors, although to a lesser degree (Fig. 2B). 
Although the existence of two adenine nucleotide/nucleo- 
side binding sites in mammalian adenylyl cyclases is widely 
accepted, the specificity towards different ligands remains to 
be established. A recent study on AC I, expressed in Sf9 cells, 
has indicated that substrate ATP also interfered with P-site 
ligands [20]. On the other hand, typical P-site ligands, as 2',5'- 
dideoxyadenosine d rivatives, affected the catalytic site as 
well. In a recent paper, Tang et al. [14] set up a series of point 
mutations of conserved charged amino acids in AC I. They 
observed in several cases linkage of reduction of affinities for 
substrate ATP and P-site inhibitors and therefore suggested 
that both ligands may bind to different conformational states 
of the same site. 
A straightforward approach for identification of a distinct 
binding site on a polypeptide chain consists in the use of 
affinity labeling in combination with chemical and enzymatic 
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Fig. 6. Sequence alignment of different adenylyl cyclases and guany- 
lyl cyclases. Shown are regions homologous to the proposed ATP 
binding site of AC I. Alignment follows the consensus equence of 
the ATP binding motif G(X0_z)KG(X0_5)L/M(X0_r)S/T suggested 
by Peterkofsky et al. [5], with a slight modification (L/M instead of 
L). Amino acid symbols of this motif are highlighted by dark boxes, 
symbols of other identical or conserved amino acids are marked by 
gray boxes. Numbers refer to homologous equences from adenylyl 
or guanylyl cyclases taken from the following references: (a) Kru- 
pinski et al. [3]; (b) Feinstein et al. [25]; (c) Bakalyar and Reed 
[26]; (d) Gao and Gilman [27]; (e) Wallach et al. [1]; (f) Premont et 
al. [28]; (g) Watson etal. [29]; (h) Levin et al. [30]; (i) Young et al. 
[31]; (j) Beuve et al. [32]; (k) Glaser et al. [33]; (1) Robertson et al. 
[34]; (m) Chinkers et al. [35]; (n) Yuen etal. [36]. The localization 
of the E3 and E4 peptides obtained from GIu-C cleavage (this 
study) of AC I is also indicated. 
fragmentation. In the present study, this has been achieved 
with NCS (cleaving at tryptophan residues) and with the en- 
doproteinases Asp-N and Glu-C. 
Fig. 5 is a schematic presentation of the C-terminal part of 
AC I displaying the numbers of amino acids at which chemi- 
cal and enzymatic fragmentation are likely to occur. The pre- 
sumptive epitopes of the monoclonal antibodies are shown in 
context. The present study infers that the smallest labeled 
peptide that could be detected was the 25 amino acid sequence 
V1°27-E 1°51. The identity of this 2.9 kDa peptide, termed E4, 
was further corroborated by its failure to be precipitable by 
antibody BBC2 (not shown). E4 comprises a GXI/  
VXVKGKG sequence present in eight of the nine mammalian 
adenylyl cyclases so far cloned. Only type VII I  adenylyl cy- 
clase has a somewhat modified motif  [21]. 
Fig. 6 shows the alignment of relevant sequences of several 
adenylyl cyclases and guanylyl cyclases. It is evident that the 
consensus equence G(X0-7)KG(X0_4)L(X0_~)S/T [5] is essen- 
tially verified for most eukaryotic and prokaryotic adenylyl 
cyclases. Furthermore a membrane bound and a soluble gua- 
nylyl cyclase were included, also fitting this motif. The lysine 
residue in this motif  has been shown to be essential for cata- 
lytic activity in the case of the enzymes from B. pertussis (K 5s) 
and B. anthracis (K 346) by mutagenesis [22,23]. In contrast, 
Tang et al. [14] have mutated K 1°49 in AC I and found no 
change in Km and Vm~x but enhancement of Ki for 2'-deox- 
y ,3 ' -AMP by a factor of 8. However, since bacterial adenylyl 
cyclases have a KG instead of a KGKG motif, the equiva- 
lence of the lysines is questionable. 
Recently it has been found that an active adenylyl cyclase 
may be constructed solely from cytosolic segments C la  and 
C2a, segments C lb  and C2b therefore being dispensable for 
catalytic activity [24]. The putative ATP binding site suggested 
in the present paper would be located at the C-terminal end of 
domain C2a. 
Although the structure of eukaryotic adenylyl cyclases is 
symmetric, no labeling of a corresponding site in subdomain 
C la  could be detected here. It is of interest hat the labeled E4 
peptide also has the protein kinase A consensus sequence 
RRGSYR.  Nevertheless, labeling by [73zP]8-Na-ATP was 
clearly due to photolysis rather than phosphoryl transfer. 
The precise identification of the labeled amino acid remains 
to be determined, e.g. by advanced mass spectrometric tech- 
niques. Because of the uncertainty in discrimination between 
substrate and inhibitor sites, similar studies with radiolabeled 
adenosine derivatives, as developed by Shoshani et al. [20], 
seem to be necessary. 
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